Company intelligence / Profile preview
Riverstone Holdings
Likely Copenhagen or wider Hovedstaden, Hovedstaden, Denmark
- Ownership
- Private
- Development stage
- Other
01
Overview
River Stone Biotech produces FDA/EMA/WHO-approved specialty alkaloid APIs such as buprenorphine, naloxone, and naltrexone using a proprietary hybrid fermentation/chemistry platform for opioid addiction, overdose, and pain—enabling more sustainable and cost-effective production
- Therapeutic areas
- NeurologyPsychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Not publicly listed; company is open to industry and academic partnerships
Beyond the preview
Go deeper on Riverstone Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Riverstone Holdings.